Plus Therapeutics' CNSide Diagnostic Platform Cuts Healthcare Costs by 40% for Cancer Patients
PSTV has more than doubled off its 52-week low of $2.9 on light trading volume (0.4× avg).
Summary
Plus Therapeutics announced that its CNSide diagnostic platform demonstrated a significant 40% reduction in healthcare costs for patients with Leptomeningeal Metastases (LM), according to a new health economics study. This study, co-authored with Harvard and recognized at the ISPOR Annual Meeting, provides strong validation for CNSide's value proposition. The substantial cost savings are crucial for securing broader payer agreements and driving commercial adoption, directly impacting the company's revenue potential for this key diagnostic product.
At the time of this announcement, PSTV was trading at $6.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.4M. The 52-week trading range was $2.90 to $23.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.